Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension

A randomized, multicenter study

Hae Jin Kim, Seung Jin Han, Dae Jung Kim, Hak Chul Jang, Soo Lim, Sung Hee Choi, Yong Hyun Kim, Dong Hyun Shin, Se Hwa Kim, Tae Ho Kim, Yu Bae Ahn, Seung Hyun Ko, Nan Hee Kim, Ji A Seo, Ha Young Kim, Kwan Woo Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/Aims: Oxidative stress plays an important role in the pathogenesis and progression of diabetic complications and antagonists of renin-angiotensin system and amlodipine have been reported previously to reduce oxidative stress. In this study, we compared the changes in oxidative stress markers after valsartan and amlodipine treatment in type 2 diabetic patients with hypertension and compared the changes in metabolic parameters. Methods: Type 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks. We measured serum nitrotyrosine levels as an oxidative stress marker. Metabolic parameters including serum glucose, insulin, lipid profile, and urine albumin and creatinine were also measured. Results: After 24 weeks of valsartan or amlodipine treatment, systolic and diastolic blood pressure decreased, with no significant difference between the groups. Both groups showed a decrease in serum nitrotyrosine (7.74 ± 7.30 nmol/L vs. 3.95 ± 4.07 nmol/L in the valsartan group and 8.37 ± 8.75 nmol/L vs. 2.68 ± 2.23 nmol/L in the amlodipine group) with no significant difference between the groups. Other parameters including glucose, lipid profile, albumin-to-creatinine ratio, and homeostasis model assessment of insulin resistance showed no significant differences before and after treatment in either group. Conclusions: Valsartan and amlodipine reduced the oxidative stress marker in type 2 diabetic patients with hypertension.

Original languageEnglish
Pages (from-to)497-504
Number of pages8
JournalKorean Journal of Internal Medicine
Volume32
Issue number3
DOIs
Publication statusPublished - 2017 May 1

Fingerprint

Multicenter Studies
Valsartan
Oxidative Stress
Amlodipine
Hypertension
Albumins
Creatinine
Serum
Blood Pressure
Lipids
Glucose
Diabetes Complications
Renin-Angiotensin System
Antihypertensive Agents
Insulin Resistance
Homeostasis
Therapeutics
Valsartan Drug Combination Amlodipine
Urine
Insulin

Keywords

  • Amlodipine
  • Diabetes mellitus
  • Oxidative stress
  • Type 2
  • Valsartan

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension : A randomized, multicenter study. / Kim, Hae Jin; Han, Seung Jin; Kim, Dae Jung; Jang, Hak Chul; Lim, Soo; Choi, Sung Hee; Kim, Yong Hyun; Shin, Dong Hyun; Kim, Se Hwa; Kim, Tae Ho; Ahn, Yu Bae; Ko, Seung Hyun; Kim, Nan Hee; Seo, Ji A; Kim, Ha Young; Lee, Kwan Woo.

In: Korean Journal of Internal Medicine, Vol. 32, No. 3, 01.05.2017, p. 497-504.

Research output: Contribution to journalArticle

Kim, HJ, Han, SJ, Kim, DJ, Jang, HC, Lim, S, Choi, SH, Kim, YH, Shin, DH, Kim, SH, Kim, TH, Ahn, YB, Ko, SH, Kim, NH, Seo, JA, Kim, HY & Lee, KW 2017, 'Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: A randomized, multicenter study', Korean Journal of Internal Medicine, vol. 32, no. 3, pp. 497-504. https://doi.org/10.3904/kjim.2015.404
Kim, Hae Jin ; Han, Seung Jin ; Kim, Dae Jung ; Jang, Hak Chul ; Lim, Soo ; Choi, Sung Hee ; Kim, Yong Hyun ; Shin, Dong Hyun ; Kim, Se Hwa ; Kim, Tae Ho ; Ahn, Yu Bae ; Ko, Seung Hyun ; Kim, Nan Hee ; Seo, Ji A ; Kim, Ha Young ; Lee, Kwan Woo. / Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension : A randomized, multicenter study. In: Korean Journal of Internal Medicine. 2017 ; Vol. 32, No. 3. pp. 497-504.
@article{92878df1461440a2a5873d022ce58a51,
title = "Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: A randomized, multicenter study",
abstract = "Background/Aims: Oxidative stress plays an important role in the pathogenesis and progression of diabetic complications and antagonists of renin-angiotensin system and amlodipine have been reported previously to reduce oxidative stress. In this study, we compared the changes in oxidative stress markers after valsartan and amlodipine treatment in type 2 diabetic patients with hypertension and compared the changes in metabolic parameters. Methods: Type 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks. We measured serum nitrotyrosine levels as an oxidative stress marker. Metabolic parameters including serum glucose, insulin, lipid profile, and urine albumin and creatinine were also measured. Results: After 24 weeks of valsartan or amlodipine treatment, systolic and diastolic blood pressure decreased, with no significant difference between the groups. Both groups showed a decrease in serum nitrotyrosine (7.74 ± 7.30 nmol/L vs. 3.95 ± 4.07 nmol/L in the valsartan group and 8.37 ± 8.75 nmol/L vs. 2.68 ± 2.23 nmol/L in the amlodipine group) with no significant difference between the groups. Other parameters including glucose, lipid profile, albumin-to-creatinine ratio, and homeostasis model assessment of insulin resistance showed no significant differences before and after treatment in either group. Conclusions: Valsartan and amlodipine reduced the oxidative stress marker in type 2 diabetic patients with hypertension.",
keywords = "Amlodipine, Diabetes mellitus, Oxidative stress, Type 2, Valsartan",
author = "Kim, {Hae Jin} and Han, {Seung Jin} and Kim, {Dae Jung} and Jang, {Hak Chul} and Soo Lim and Choi, {Sung Hee} and Kim, {Yong Hyun} and Shin, {Dong Hyun} and Kim, {Se Hwa} and Kim, {Tae Ho} and Ahn, {Yu Bae} and Ko, {Seung Hyun} and Kim, {Nan Hee} and Seo, {Ji A} and Kim, {Ha Young} and Lee, {Kwan Woo}",
year = "2017",
month = "5",
day = "1",
doi = "10.3904/kjim.2015.404",
language = "English",
volume = "32",
pages = "497--504",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "3",

}

TY - JOUR

T1 - Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension

T2 - A randomized, multicenter study

AU - Kim, Hae Jin

AU - Han, Seung Jin

AU - Kim, Dae Jung

AU - Jang, Hak Chul

AU - Lim, Soo

AU - Choi, Sung Hee

AU - Kim, Yong Hyun

AU - Shin, Dong Hyun

AU - Kim, Se Hwa

AU - Kim, Tae Ho

AU - Ahn, Yu Bae

AU - Ko, Seung Hyun

AU - Kim, Nan Hee

AU - Seo, Ji A

AU - Kim, Ha Young

AU - Lee, Kwan Woo

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background/Aims: Oxidative stress plays an important role in the pathogenesis and progression of diabetic complications and antagonists of renin-angiotensin system and amlodipine have been reported previously to reduce oxidative stress. In this study, we compared the changes in oxidative stress markers after valsartan and amlodipine treatment in type 2 diabetic patients with hypertension and compared the changes in metabolic parameters. Methods: Type 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks. We measured serum nitrotyrosine levels as an oxidative stress marker. Metabolic parameters including serum glucose, insulin, lipid profile, and urine albumin and creatinine were also measured. Results: After 24 weeks of valsartan or amlodipine treatment, systolic and diastolic blood pressure decreased, with no significant difference between the groups. Both groups showed a decrease in serum nitrotyrosine (7.74 ± 7.30 nmol/L vs. 3.95 ± 4.07 nmol/L in the valsartan group and 8.37 ± 8.75 nmol/L vs. 2.68 ± 2.23 nmol/L in the amlodipine group) with no significant difference between the groups. Other parameters including glucose, lipid profile, albumin-to-creatinine ratio, and homeostasis model assessment of insulin resistance showed no significant differences before and after treatment in either group. Conclusions: Valsartan and amlodipine reduced the oxidative stress marker in type 2 diabetic patients with hypertension.

AB - Background/Aims: Oxidative stress plays an important role in the pathogenesis and progression of diabetic complications and antagonists of renin-angiotensin system and amlodipine have been reported previously to reduce oxidative stress. In this study, we compared the changes in oxidative stress markers after valsartan and amlodipine treatment in type 2 diabetic patients with hypertension and compared the changes in metabolic parameters. Methods: Type 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks. We measured serum nitrotyrosine levels as an oxidative stress marker. Metabolic parameters including serum glucose, insulin, lipid profile, and urine albumin and creatinine were also measured. Results: After 24 weeks of valsartan or amlodipine treatment, systolic and diastolic blood pressure decreased, with no significant difference between the groups. Both groups showed a decrease in serum nitrotyrosine (7.74 ± 7.30 nmol/L vs. 3.95 ± 4.07 nmol/L in the valsartan group and 8.37 ± 8.75 nmol/L vs. 2.68 ± 2.23 nmol/L in the amlodipine group) with no significant difference between the groups. Other parameters including glucose, lipid profile, albumin-to-creatinine ratio, and homeostasis model assessment of insulin resistance showed no significant differences before and after treatment in either group. Conclusions: Valsartan and amlodipine reduced the oxidative stress marker in type 2 diabetic patients with hypertension.

KW - Amlodipine

KW - Diabetes mellitus

KW - Oxidative stress

KW - Type 2

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=85019935429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019935429&partnerID=8YFLogxK

U2 - 10.3904/kjim.2015.404

DO - 10.3904/kjim.2015.404

M3 - Article

VL - 32

SP - 497

EP - 504

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 3

ER -